fda approves first oral glp-1 obesity drug august 14 2025 A new option is now part of medicine. approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, for adults with obesity or overweight with at least one weight-related GLP-1 RA Adherence Shows Drop-Off

Since IBS is a functional gastrointestinal disorder, practitioners and their patients should be cognizant about how any potential intervention impacts other functional aspects of a patients health

Neither PAP nor GLP-1s treat the underlying cause of OSA

A: People who dislike needles, prefer simpler routines, travel frequently, or struggled with injectable adherence may prefer the pill format

Its foundational with these common-named substances that are in early-stage research, youll see many, many different forms. One of the panelists who voted to restore BPC-157, David Pope, Chief Pharmacy Officer at XiFin Pharmacy Solutions, cited concerns of increased gray market access to peptides

The Journal of Clinical Endocrinology and Metabolism

Obesity in older adults: effect of degree of weight loss on cardiovascular markers and medications